Objectives: To determine the role of type 1 cytokines as predictors of response to treatment of genital HPV lesions with laser ablation with or without adjuvant systemic interferon a2b (IFN-a). Methods: Measurement of serum interleukin 2 (IL-2), IL-2 soluble receptor a (sIL-2a), interferon y, and human papilloma virus (HPV) DNA in patients undergoing treatment of genital HPV lesions with carbon dioxide laser and systemic IFN-a. A randomised, placebo controlled study of 92 cases with 6 months of follow up. Results: High IL-2/sIL-2a was associated with 60% to 70% protection against recurrences both in the IFN-a and placebo groups (OR = 0.4, 90%, CI 01-2.5; OR = 0.3, 90% CI 0.0-1.8, respectively). Diagnostic phase serum IL-2 predicted favourable outcome (OR = 0.2, 90% CI 0.0-1 0) in women with high load of HPV DNA or HPV16/18 DNA regardless of the adjuvant therapy. Conclusions: Serum IL-2 determinations may identify women with good prognosis following laser ablation of genital HPV lesions.
Introduction
Encouraged by successful use of human leucocyte interferon (interferon a, IFN-a) in the treatment of recurrent respiratory papillomatosis'-3 several clinical trials have been conducted on the treatment of genital human papilloma virus (HPV) infections with interferons (for a review see Cirelli and Tyring4). Surgical excision with adjuvant systemic IFN-a gives better results than other treatment methods. Of nine studies reported47 only tWo6 7 have failed to demonstrate beneficial effects.
Combination of IFN-a with other biological response modifiers, especially interleukin 2 (IL-2) has shown additive or synergistic effects in tumour immunotherapy.8 10 On the other hand, increased expression of both IL-2 and soluble IL-2 receptor a (sIL-2ct) contribute to allograft rejection," and have recently been associated with the extent of HPV positive cervical intraepithelial neoplasia (CIN).12 3 These effects are largely mediated by the augmentation of cytotoxic T cell (CTL) response, normally stimulated by IL-2 producing T helper (Thl) cells. Interplay between CTLs and Thl cells is presumed an important determinant of the clinical course of cervical HPV infection. The purpose of our study was to evaluate determinants of treatment outcome of genital HPV lesions with adjuvant IFN-ax with special emphasis on the Thl arm of cell mediated immunity as reflected by the serum cytokines interferon y (IFN-y) and IL-2, and the sIL-2a.
Materials and methods
The study population, consisting of 100 women (mean age 24.1 years, range referred to the gynaecological outpatient clinic, University Hospital, Helsinki, Finland, has been described in detail. We then divided both the IFN-cx group and the placebo group into two subgroups according to the presence or absence of HPV DNA as determined by the dot blot assay (high/low viral load). The predictors of complete response remained the same in patients with high load of HPV DNA (table 3) . Thus, for the final analyses the two treatment groups were combined. Patients with high IL-2/sIL- Other combinations, such as IFN-cx and IFN-, or IFN-ot and retinoids for the treatment of refractory warts have been suggested.4 21 22 Owing to the small numbers we were not able to confim or refute this. Studies on new combinations of biological response modifiers in the treatment of genital HPV lesions are needed. 
